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Management and prognosis of status
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Summary
Background: The treatment of status epilepti-
cus (SE) is based on relatively little evidence al-
though several guidelines have been published. A
recent study reported a worse SE prognosis in a
large urban setting as compared to a peripheral
hospital, postulating better management in the
latter.The aim of this study was to analyse SE epi-
sodes occurring in different settings and address
possible explanatory variables regarding outcome,
including treatment quality.
Methods:Over six months we prospectively re-
corded consecutive adults with SE (fit lasting five
or more minutes) at the Centre Hospitalier Uni-
versitaire Vaudois (CHUV) and in six peripheral
hospitals (PH) in the same region. Demograph-
ical, historical and clinical variables were col-
lected, including SE severity estimation (STESS
score) and adherence to Swiss SE treatment guide-
lines. Outcome at discharge was categorised as
“good” (return to baseline), or “poor” (persistent
neurological sequelae or death).
Results: Of 54 patients (CHUV: 36; PH 18),
33% had a poor outcome.Whilst age, SE severity,
percentage of SE episodes lasting less than 30
minutes and total SE duration were similar, fewer
patients had a good outcome at the CHUV (61%
vs 83%; OR 3.57; 95% CI 0.8–22.1). Mortality
was 14% at the CHUV and 5% at the PH. Most
treatments were in agreement with national guide-
lines, although less often in PH (78% vs 97%, P =
0.04).
Conclusion: Although not statistically signifi-
cant, we observed a slightly worse SE prognosis in
a large academic centre as compared to smaller
hospitals. Since SE severity was similar in the two
settings but adherence to national treatment
guidelines was higher in the academic centre, fur-
ther investigation on the prognostic role of SE
treatment and outcome determinants is required.









Status epilepticus (SE) occurs yearly in at least
10/100000 people in central Europe [1, 2] and is
related to considerable morbidity and mortality
[3]. Whilst its prognosis is essentially related to
underlying aetiology and age [4, 5], it remains un-
clear if and to what extent pharmacological treat-
ment influences SE outcome. Clinical studies fo-
cusing on SE treatment are rare and their quality
is considered poor. A 2005 Cochrane review iden-
tified only eleven publications reaching valid con-
clusions regarding initial treatment [6]: lorazepam
appears superior to diazepam or phenytoin [6].
Current European therapeutic recommendations
are mostly based upon expert opinion [7–10]. In
most guidelines, SE management is based on a
three-step approach, starting with benzodi-
azepines, followed by classical antiepileptic drugs
(mostly phenytoin, valproate, phenobarbital), and
finally pharmacological coma induction with an
anaesthetic agent (barbiturates, propofol, or mida-
zolam) [3, 10]. Coma induction is indicated for pa-
tients with SE resistant to the first two steps. In
view of potential risks related to both treatment
and prolonged mechanical ventilation and
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immobilisation, it may be advisable to balance the
risks and benefits of this therapeutic approach [11,
12], especially in patients with potentially less dan-
gerous forms of SE [13]. Given the paucity of
evidence-based data, clinicians often manage SE
patients as they feel best, generating divergent
treatment “schools” [12].
A recent retrospective Italian study suggested
that SE prognosis in adults varies according to
hospital type and location: a peripheral rural hos-
pital had a lower thirty-day mortality in compari-
son too a large academic urban centre (7% vs
33%) [14]. However, an epidemiological survey
conducted ten years ago in French-speaking Swit-
zerland showed a relatively low mortality in both
urban (7%, Geneva) and rural regions (12%,
Valais). A recent study on convulsive SE from
Ethiopia reported a case fatality of 20% [15],
which appears broadly comparable with SE mor-
tality in western countries, in spite of a greater la-
tency to diagnosis and the lack of intravenous
AED formulations and raises the possibility that
SE treatment might have a relatively limited
impact.
The goal of this study was to determine how
SE episodes are managed and if SE treated in a
large urban hospital has a different prognosis as
compared to regional or district hospitals. Fur-
thermore, possible explanations were addressed,
including referral bias and, in view of the increas-
ing popularity of therapeutic guidelines in various
clinical settings, treatment quality.
Methods
Design, participating hospitals, patients and
SE definition
This is a prospective exploratory case series of adults
with SE conducted between 30thMarch and 29th Septem-
ber 2008 (six consecutive months) in the French-speaking
part of Switzerland at the Centre Hospitalier Universitaire
Vaudois (CHUV), five regional hospitals and one epilepsy
clinic (La-Chaux-de-Fonds, Fribourg, Lavigny, Morges,
Neuchâtel-Pourtalès, St-Loup). The study was approved
by our ethics committee. Consecutive patients aged 16 and
older presenting with SE (incident or recurrent) were in-
cluded. SE was defined as an epileptic seizure of any clini-
cal semiology, lasting for at least five minutes, or two or
more seizures of shorter duration without intercurrent re-
turn to baseline clinical conditions [16]. In accordance with
the vast majority of available studies,EEGwas not required
for diagnosis, since SE is a clinical entity [3]. However, the
diagnosis of non-convulsive SE implied by definition a
concomitant ictal EEG recording. Paediatric patients who
have a different profile of causes and outcome [1, 17], and
patients with post anoxic SE,which is often associated with
a dismal prognosis [18], were excluded.
Data collection
Demographical, historical and clinical variables were
prospectively collected by means of a standardised anony-
mous form in each participating centre by the on-site
consultant neurologist or research fellow (Fribourg). At
the CHUV, case assessment was performed by the staff of
the epilepsy unit (four physicians). In case of unclear is-
sues telephone contact with the participating centres was
initiated. The following patient characteristics were re-
corded: age, gender, estimated body weight. Furthermore,
we recorded location of SE onset (in-hospital vs out of
hospital) and categorised extent of impairment of con-
sciousness before treatment administration (alert, con-
fused or somnolent, defined as arousable and interactive,
vs stuporous, defined as arousable but not interactive, or
comatose), clinical seizure type (simple-partial, absence,
myoclonic without coma, and complex-partial, vs gener-
alised convulsive and nonconvulsive in coma) and history
of previous seizures (yes vs no).Absence SE, complex-par-
tial SE, simple-partial SE without movements, and non-
convulsive SE on coma were defined as nonconvulsive
SE.Type of previous antiepileptic treatment, SE duration
before treatment institution and until seizure control,
agents used, including doses, and SE aetiology were col-
lected. Outcome at hospital discharge was categorised as
return to baseline clinical condition, discharge with neu-
rological sequelae or death.
Data analysis and statistics
After completion of all data collection, two authors
(AOR, JN) consensually assessed if the pharmacological
management of the index SE episode was in agreement
with the most recently published Swiss guidelines [8].The
suggested protocol (drug types, dosages and sequence of
administration) was considered as “standard”. Benzodi-
azepines are recommended as the first-line treatment
within 5–10 minutes (four alternatives are proposed: lo-
razepam 0.1 mg/kg, diazepam 0.25 mg/kg, clonazepam
0,025 mg/kg, or midazolam 0.1–0.3 mg/kg). If SE persists,
phenytoin (17 mg/kg under cardiac monitoring, followed
by a maintenance dose) or valproate (15–25 mg/kg, also
followed by a maintenance dose) should be given, starting
within 15 minutes of the SE onset (second-line). The
third-line is represented by the administration of one of
four anaesthetic agents: midazolam bolus 0.2 mg/kg, fol-
lowed by 0.05–0.8 mg/kg/h (unclear in the original text,
but taken from other recommendations [19, 20]); propo-
fol bolus 1–2 mg/kg, then 2–10 mg/kg/h; phenobarbital
bolus 5–20 mg/kg, followed by 0.5–1 mg/kg/h; or thio-
pental bolus 1.5 mg/kg/h, then 3–5 mg/kg/h. Standard
treatment allowed inclusion of levetiracetam as a second-
line regimen, even if not mentioned in the guidelines,
since it is increasingly used to treat SE in patients with po-
tential side effects to enzyme-inducing agents [11, 21, 22],
using a loading dosage of at least 15 mg/kg. A previously
validated clinical prognostic score (STESS) was calcu-
lated and categorised as good (<3) vs poor (≥3) [23, 24].
Aetiological classification was assessed in accordance with
current guidelines [25].
A Stata software, version 9.2 for Windows, was used
for statistical calculations. Normally distributed continu-
ous variables were expressed as mean ± standard devia-
tion; otherwise as median and range. Comparisons be-
tween the CHUV and the outside hospitals were per-
formed with 2-sided Fisher exact tests for categorical or
with the t-test or Mann-Whitney U-test, for continuous
or ordinal variables, respectively. Significance was set at P
<0.05. No correction for multiple comparisons was ap-
plied because of the exploratory character of this study.
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Results
During the study period, we recorded 54 pa-
tients treated for SE in the seven participating
centres.There were no repetitive episodes. By the
end of their hospitalisation, all patients had had at
least one EEG recording.Thirty-six subjects were
included at the CHUV and 18 in the six other hos-
pitals (five in La Chaux-de-Fonds, three each in
Lavigny,Neuchâtel and Fribourg, and two each in
Morges and St-Loup). Four patients in the latter
group were subsequently transferred to the
CHUV, whereas one CHUV patient was initially
managed in another country.
The table reports clinical data according to
the site of treatment. Age, frequency of SE onset
outside the hospital, prevalence of a history of pre-
vious seizures, SE severity according to the STESS
score, frequency of nonconvulsive SE, prevalence
of SE episodes less than 30 minutes, and total SE
duration were similarly distributed among both
groups. Several other items showed potentially
important differences between treatment sites.
However, none of these reached statistical signifi-
cance. More subjects with significant impairment
of consciousness, severe seizure types, SE refrac-
tory to the first two treatment lines and needing
therapeutic coma induction, but also with a cryp-
togenic SE episode, were managed at outside hos-
pitals. A longer latency to treatment was observed
at the CHUV, where patients tended to present
more often with SE arising in-hospital and with
acute symptomatic aetiologies. Regarding out-
come, fewer patients returned to baseline clinical
conditions at the CHUV (61% vs 83%).The odds
ratio for poor outcome (i.e., death or neurological
sequelae at discharge) at the CHUV as compared
to outside hospitals was 3.57 (95% CI: 0.8–22.1).
Treatment of most patients (91%) corre-
sponded to the national guidelines, but less so in
the peripheral hospitals as compared to the
CHUV (22% vs 3%, P = 0.04).Nevertheless, non-
adherence to treatment guidelines was not associ-
ated with a worse outcome (P = 0.66). Likelihood
of return to baseline for patients with nonconvul-




treated at the CHUV
and at six outside
hospitals.
CHUV Other hospitals P Test †
Patients 36* 18**
Female 22 (61%) 7 (39%) 0.154 Fisher
Age (mean, SD) 57 (19) 56 (19) 0.840 t
Onset outside hospital 32 (89%) 13 (72%) 0.142 Fisher
Known previous seizures 20 (56%) 11 (61%) 0.776 Fisher
Consciousness before treatment
– awake, somnolent, or confused 20 (56%) 5 (28%) 0.082 Fisher
– stuporous or comatose 16 (44%) 13 (72%)
Seizure type
– simple- or complex-partial status 22 (61%) 7 (39%) 0.154 Fisher
– generalised convulsive or nonconvulsive
status in coma
14 (39%) 11 (61%)
– Nonconvulsive SE 15 (42%) 7 (39%) 1.000 Fisher
STESS score (median, range) 2 (0-5) 2 (0-4) 0.431 U
STESS score ≥3 15 (42%) 8 (44%) 1.000 Fisher
Duration before treatment
(minutes; median, range)
105 (5 min–2years) 60 (5 min–2 weeks) 0.089 U
SE lasting <30 minutes 5 (14%) 3 (17%) 1.000 Fisher
Total duration (minutes; median, range) 135 (10 min–2.5years) 150 (10 min–90 days) 0.854 U
SE refractory to first two treatment lines 5 (14%) 7 (39%) 0.079 Fisher
Coma induction for SE treatment 2 (6%) 3 (17%) 0.319 Fisher
Treatment not in agreement with Swiss
guidelines
1 (3%) 4 (22%) 0.038 Fisher
Acute symptomatic aetiology 20 (56%) 7 (39%) 0.387 Fisher
Cryptogenic aetiology 6 (17%) 6 (33%) 0.184 Fisher
Outcome
– Returned to baseline 21 (61%) 15 (83%) 0.260 Fisher
– Survived with sequelae 10 (28%) 2 (11%)
– Death 5 (14%) 1 (5%)
Fisher: Fisher exact test; t: Student t-test; U: Mann-Whitney U-test; * one patient referred from abroad; ** four patients subsequently
referred to the CHUV
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(6/15 [40%] vs 15/21 [71%]) as compared to the
outside hospitals (6/7 [86%] vs 9/11 [81%]), with-
out reaching significance (P = 0.230, Fisher). Of
the four patients referred to the CHUV from out-
side hospitals, only two returned to baseline con-
ditions (one deceased, one discharged with seque-
lae). The patient referred to the CHUV from
abroad was discharged with neurological deficits.
In 8/54 patients (15%) SE lasted between 5 and 29
minutes. In these subjects, the outcomes were not
different as compared to SE episodes lasting 30
minutes or longer (5/8 vs 31/46 returned to base-
line, P = 1.0).
Discussion
This study confirms that the management of
SE is difficult and the outcome often adverse. In-
deed, one third of patients had neurological
sequelae or died. The treatment received was in
agreement with the national guidelines in the vast
majority of instances. However, a larger propor-
tion of treatment corresponded to national guide-
lines in the university centre as compared to pe-
ripheral hospitals. Furthermore, our data seem to
indicate that SE patients treated in a university
hospital tend to have a worse prognosis than those
managed at regional centres. Finally, seizures last-
ing between 5 and 29 minutes account for a mi-
nority (15%) of ascertained cases.
Prognostic variability among different hospi-
tal types raises several questions regarding possi-
ble explanations. Indeed, a higher mortality in a
tertiary referral centre appears counterintuitive as
coverage of a university hospital typically implies
a neurologist available 24/24 h, 7/7 d, and EEG
availability every day, whereas in a regional or dis-
trict hospital, a neurologist is on call during work-
ing hours only and EEG availability is restricted.
Intensive care unit resources are also more widely
available in university hospitals.Whilst the afore-
mentioned Italian study suggested a better SE
management in the rural centre, [14] this does not
seem to be the case in the present study, where
treatment in the university hospital was more of-
ten in agreement with guidelines. Quite surpris-
ingly in our study, peripheral hospitals tended to
have more patients with severe impairment of
consciousness, generalised convulsive seizures and
refractory SE episodes; factors related to a worse
prognosis [4, 5, 17, 26].Whilst age and history of
previous seizures were similar among groups,
acute symptomatic aetiologies and longer latency
to treatment (somewhat linked to worse prognosis
[4, 5, 17, 26]) showed a trend in favour of the
CHUV. Cryptogenic SE, probably related to bet-
ter outcome [27], was more frequent in peripheral
hospitals. All these predictors very likely balanced
themselves out. SE severity, estimated by the
STESS score, was comparable in the two settings.
Other factors must therefore account for the ob-
served prognostic difference. The presence of co-
morbidities was not formally assessed in this study.
These may be supposed to be more frequent in a
tertiary centre, where patients with in-hospital SE
tended to be more prevalent. It can also be postu-
lated that patients tend to leave the university
hospital to be referred to other centres or rehabil-
itation facilities earlier as compared to peripheral
hospitals, thus leading to an information bias. Un-
fortunately, our data do not allow retrieval of hos-
pitalisation length. Furthermore, we cannot ex-
clude the possibility that the yield and quality of
case ascertainment was critically different, as
might be suggested by a higher prevalence of
complex-partial and simple partial SE at the aca-
demic centre. Indeed, formal data verification by a
coordinating authority was not performed, possi-
bly generating more “generalised convulsive
seizures” and “stupor/coma” in the peripheral set-
ting, where neurological evaluations on admission
and follow-up are less thorough than in the uni-
versity centre.
This study produced a further important find-
ing. Only a limited proportion of SE episodes
(15%) lasted less than 29 minutes. A minimal sei-
zure duration of 30 minutes is generally used in
epidemiological surveys. However, in clinical
practice, a time frame of 5 minutes has been advo-
cated to encourage early pharmacological treat-
ment [16]. One study found that 43% of seizures
lasting between 10 and 29 minutes subsided spon-
taneously, whereas patients with longer seizures
more often needed to be treated with an AED
[28].This ambispective study (short episodes were
collected retrospectively and longer episodes pro-
spectively) reported a higher prevalence (26%) of
“short” SE episodes as compared to our survey
and a clear mortality difference (19% in pro-
longed SE vs 3% in seizures <30 minutes, P
<0.001). A larger study is needed to determine
whether these differences are related to diverging
study designs, different sample sizes, geographical
location or chance.
Incomplete adherence to treatment guide-
lines, occurring in a minority of cases, was not sig-
nificantly associated to SE outcome. Surprising at
first glance, this observation should be reframed:
SE treatment relies on relatively low evidence,
[29] and prognosis is mostly influenced by aetiol-
ogy [4, 5, 26, 30], age and extent of consciousness
impairment represent other important predictors
[4, 26, 30]. In fact, previous observations by our
group focusing on the administration of “aggres-
sive” SE treatment, i.e., pharmacological coma in-
duction, do not suggest that a specific treatment
approach correlates with a better prognosis [24].
This preliminary study is limited by its size
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leading to a reduced power, by the possibility of
incomplete case ascertainment in the peripheral
hospitals, resulting in potential information bias,
and by the lack of formally standardised outcome
measures among the centres. However, it appears
unlikely that recording of more simple-partial and
complex-partial SE episodes in the peripheral set-
ting would inverse the trend of prognosis differ-
ence, since these SE forms are probably less prone
to result in death. Nevertheless, it is paramount to
address these issues, including a thorough assess-
ment of case severity and comorbidity in a larger
prospective survey.We believe that such a study, if
well-designed, may help to clarify if the prognostic
difference between SE cases treated in small and
large academic is real and, if so, identify the rea-
sons and address the real impact of SE treatment
guidelines in this context. The identification of
modifiable features and the exact role of baseline
patient characteristics and hospital settings should
allow the discovery of practical ways to improve
the care of patients suffering from SE.
A. Carruzzo, MD; E. Hecker, MD; F. Huber, MD;
M.Maeder-Ingvar,MD; C.Naegeli,MD and P.-A. Rapin,
MD helped in data collection.
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